


AfriKADIA Consortium – EDCTP program
Jorge Alvar
LEAP meeting, Uganda, 3 Oct. 2018



SSG-PM: an improvement, but with limitations

- Efficacy of 91% at 6 months
- 17 days of 2 injections
- Toxicity related to SSG
- Lower efficacy (81% EOT) and higher mortality (9%) in > 50y
- Not recommended for HIV-VL

Replacement of SSG by miltefosine have the potential of a safer treatment with shorter hospitalization, suitable for children and more field adapted



WP 1: Improving treatment

Phase III MF/PM clinical trial:

An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin with SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

WP2: Diagnosis

- Improving VL primary cases
- Improving ToC
- Developing predictive markers of cure

RDT (rK28, IgG1)



COMMUNITY HEALTH
WORKER



HEALTH
POST



MICROSCOPY CENTER



DISTRICT
HOSPITAL




REFERENCE
CENTRE

LAMP, IgG1 ELISA

LPA, CRA

WP3 – Capacity building

1. To strengthen research capacity in the eastern African region:
2. To improve scientific networking among LEAP members, South-South and South-North collaborations
3. To provide scientific evidence to support policy change and to strengthen communication and dissemination of research results within participating countries in eastern Africa



Afri-KA-DIA, inception meeting

